RARE Annual CAPEX
$46.77 M
-$99.36 M-67.99%
31 December 2023
Summary:
As of January 23, 2025, RARE annual capital expenditures is $46.77 million, with the most recent change of -$99.36 million (-67.99%) on December 31, 2023. During the last 3 years, it has risen by +$2.86 million (+6.52%). RARE annual CAPEX is now -67.99% below its all-time high of $146.12 million, reached on December 31, 2022.RARE CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE Quarterly CAPEX
$1.62 M
-$2.89 M-64.14%
30 September 2024
Summary:
As of January 23, 2025, RARE quarterly capital expenditures is $1.62 million, with the most recent change of -$2.89 million (-64.14%) on September 30, 2024. Over the past year, it has dropped by -$2.08 million (-56.24%). RARE quarterly CAPEX is now -97.40% below its all-time high of $62.18 million, reached on March 31, 2022.RARE Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE TTM CAPEX
$20.94 M
-$2.08 M-9.03%
30 September 2024
Summary:
As of January 23, 2025, RARE TTM capital expenditures is $20.94 million, with the most recent change of -$2.08 million (-9.03%) on September 30, 2024. Over the past year, it has dropped by -$51.20 million (-70.98%). RARE TTM CAPEX is now -85.67% below its all-time high of $146.12 million, reached on December 31, 2022.RARE TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -68.0% | -56.2% | -71.0% |
| 3 y3 years | +6.5% | -92.1% | -73.5% |
| 5 y5 years | +1047.4% | -67.9% | -15.7% |
RARE CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -68.0% | at low | -97.4% | +1.1% | -85.7% | at low |
| 5 y | 5-year | -68.0% | +88.3% | -97.4% | +1.1% | -85.7% | at low |
| alltime | all time | -68.0% | +1574.4% | -97.4% | +330.1% | -85.7% | +717.9% |
Ultragenyx Pharmaceutical CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.62 M(-64.1%) | $20.94 M(-9.0%) |
| June 2024 | - | $4.51 M(-65.9%) | $23.02 M(-34.1%) |
| Mar 2024 | - | $13.21 M(+725.7%) | $34.94 M(-25.3%) |
| Dec 2023 | $46.77 M(-68.0%) | $1.60 M(-56.7%) | $46.77 M(-35.2%) |
| Sept 2023 | - | $3.69 M(-77.5%) | $72.14 M(-23.7%) |
| June 2023 | - | $16.44 M(-34.3%) | $94.49 M(-13.3%) |
| Mar 2023 | - | $25.03 M(-7.2%) | $108.97 M(-25.4%) |
| Dec 2022 | $146.12 M(+99.9%) | $26.97 M(+3.5%) | $146.12 M(+8.1%) |
| Sept 2022 | - | $26.05 M(-15.8%) | $135.20 M(+4.2%) |
| June 2022 | - | $30.92 M(-50.3%) | $129.72 M(+9.1%) |
| Mar 2022 | - | $62.18 M(+287.5%) | $118.86 M(+62.6%) |
| Dec 2021 | $73.09 M(+66.5%) | $16.05 M(-21.9%) | $73.09 M(-7.5%) |
| Sept 2021 | - | $20.56 M(+2.4%) | $78.99 M(+27.0%) |
| June 2021 | - | $20.07 M(+22.3%) | $62.21 M(+34.6%) |
| Mar 2021 | - | $16.41 M(-25.2%) | $46.22 M(+5.3%) |
| Dec 2020 | $43.91 M | $21.95 M(+480.6%) | $43.91 M(+31.2%) |
| Sept 2020 | - | $3.78 M(-7.4%) | $33.46 M(-3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | $4.08 M(-71.0%) | $34.71 M(-3.2%) |
| Mar 2020 | - | $14.10 M(+22.6%) | $35.87 M(+44.4%) |
| Dec 2019 | $24.83 M(+509.2%) | $11.50 M(+128.5%) | $24.83 M(+71.0%) |
| Sept 2019 | - | $5.03 M(-4.0%) | $14.52 M(+38.0%) |
| June 2019 | - | $5.24 M(+71.3%) | $10.52 M(+58.0%) |
| Mar 2019 | - | $3.06 M(+156.6%) | $6.66 M(+63.4%) |
| Dec 2018 | $4.08 M(+45.9%) | $1.19 M(+15.5%) | $4.08 M(+7.7%) |
| Sept 2018 | - | $1.03 M(-25.1%) | $3.78 M(-0.0%) |
| June 2018 | - | $1.38 M(+189.9%) | $3.78 M(+36.0%) |
| Mar 2018 | - | $475.00 K(-47.2%) | $2.78 M(-0.4%) |
| Dec 2017 | $2.79 M(-72.6%) | $899.00 K(-13.0%) | $2.79 M(+9.1%) |
| Sept 2017 | - | $1.03 M(+174.7%) | $2.56 M(-43.5%) |
| June 2017 | - | $376.00 K(-22.5%) | $4.53 M(-50.8%) |
| Mar 2017 | - | $485.00 K(-27.2%) | $9.20 M(+5.6%) |
| Dec 2016 | $10.19 M | $666.00 K(-77.8%) | $8.71 M(+8.3%) |
| Sept 2016 | - | $3.00 M(-40.5%) | $8.04 M(+59.5%) |
| June 2016 | - | $5.04 M | $5.04 M |
FAQ
- What is Ultragenyx Pharmaceutical annual capital expenditures?
- What is the all time high annual CAPEX for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual CAPEX year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly CAPEX year-on-year change?
- What is Ultragenyx Pharmaceutical TTM capital expenditures?
- What is the all time high TTM CAPEX for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM CAPEX year-on-year change?
What is Ultragenyx Pharmaceutical annual capital expenditures?
The current annual CAPEX of RARE is $46.77 M
What is the all time high annual CAPEX for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual capital expenditures is $146.12 M
What is Ultragenyx Pharmaceutical annual CAPEX year-on-year change?
Over the past year, RARE annual capital expenditures has changed by -$99.36 M (-67.99%)
What is Ultragenyx Pharmaceutical quarterly capital expenditures?
The current quarterly CAPEX of RARE is $1.62 M
What is the all time high quarterly CAPEX for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly capital expenditures is $62.18 M
What is Ultragenyx Pharmaceutical quarterly CAPEX year-on-year change?
Over the past year, RARE quarterly capital expenditures has changed by -$2.08 M (-56.24%)
What is Ultragenyx Pharmaceutical TTM capital expenditures?
The current TTM CAPEX of RARE is $20.94 M
What is the all time high TTM CAPEX for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM capital expenditures is $146.12 M
What is Ultragenyx Pharmaceutical TTM CAPEX year-on-year change?
Over the past year, RARE TTM capital expenditures has changed by -$51.20 M (-70.98%)